Biofrontera Current Deferred Revenue vs Capex To Revenue Analysis

BFRIW Stock

USD 0.13 0.05 64.77%

Biofrontera Warrants financial indicator trend analysis is way more than just evaluating Biofrontera Warrants prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biofrontera Warrants is a good investment. Please check the relationship between Biofrontera Warrants Current Deferred Revenue and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera Warrants. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Biofrontera Stock please use our How to Invest in Biofrontera Warrants guide.

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biofrontera Warrants Current Deferred Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have very week relationship.

The correlation between Biofrontera Warrants' Current Deferred Revenue and Capex To Revenue is 0.2. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Biofrontera Warrants, assuming nothing else is changed. The correlation between historical values of Biofrontera Warrants' Current Deferred Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Biofrontera Warrants are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Current Deferred Revenue i.e., Biofrontera Warrants' Current Deferred Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.2

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Biofrontera Warrants' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biofrontera Warrants current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera Warrants. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Biofrontera Stock please use our How to Invest in Biofrontera Warrants guide.At this time, Biofrontera Warrants' Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 8.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 34.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	540K	1.2M	1.1M	1.5M
Interest Income	16K	175K	168K	90.6K

Depreciation And Amortization Interest Income

Biofrontera Warrants fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		-0.61	0.15	0.63	0.7	0.28	-0.74	-0.63	0.1	0.74	0.95	0.92	-0.18	0.8	0.41	0.39	-0.48	-0.77	0.67	0.71	-0.37	0.8	0.26	1.0	-0.63	0.71
Short Long Term Debt Total	-0.61		0.67	-0.35	-0.98	-0.52	0.96	0.85	-0.54	-0.33	-0.49	-0.56	0.47	-0.41	-0.11	-0.69	0.94	0.77	-0.66	-0.9	0.95	-0.52	-0.62	-0.62	0.57	-0.36
Other Current Liab	0.15	0.67		0.15	-0.54	-0.33	0.49	0.54	-0.68	0.34	0.28	0.21	0.56	0.34	0.32	-0.51	0.72	0.23	-0.32	-0.46	0.81	0.18	-0.5	0.13	0.17	0.26
Total Current Liabilities	0.63	-0.35	0.15		0.47	0.81	-0.34	-0.66	0.43	0.17	0.7	0.56	-0.37	0.37	0.83	0.75	-0.46	-0.09	0.29	0.71	-0.28	0.78	0.74	0.61	-0.92	0.09
Total Stockholder Equity	0.7	-0.98	-0.54	0.47		0.58	-0.97	-0.84	0.46	0.41	0.61	0.67	-0.4	0.53	0.27	0.7	-0.93	-0.78	0.61	0.92	-0.91	0.67	0.64	0.7	-0.63	0.43
Property Plant And Equipment Net	0.28	-0.52	-0.33	0.81	0.58		-0.38	-0.71	0.67	-0.19	0.36	0.25	-0.51	0.08	0.73	0.89	-0.72	0.03	0.1	0.75	-0.61	0.62	0.96	0.27	-0.84	-0.23
Net Debt	-0.74	0.96	0.49	-0.34	-0.97	-0.38		0.76	-0.31	-0.58	-0.6	-0.74	0.26	-0.62	-0.08	-0.57	0.83	0.9	-0.72	-0.86	0.84	-0.57	-0.47	-0.75	0.49	-0.61
Retained Earnings	-0.63	0.85	0.54	-0.66	-0.84	-0.71	0.76		-0.81	-0.09	-0.55	-0.46	0.76	-0.19	-0.34	-0.89	0.9	0.48	-0.68	-0.95	0.8	-0.56	-0.81	-0.64	0.88	-0.09
Accounts Payable	0.1	-0.54	-0.68	0.43	0.46	0.67	-0.31	-0.81		-0.5	0.06	-0.15	-0.95	-0.41	0.2	0.8	-0.72	0.04	0.34	0.63	-0.64	0.14	0.78	0.1	-0.72	-0.5
Cash	0.74	-0.33	0.34	0.17	0.41	-0.19	-0.58	-0.09	-0.5		0.64	0.89	0.48	0.94	0.01	-0.07	-0.05	-0.79	0.52	0.3	-0.05	0.46	-0.2	0.75	-0.03	0.99
Non Current Assets Total	0.95	-0.49	0.28	0.7	0.61	0.36	-0.6	-0.55	0.06	0.64		0.87	-0.17	0.78	0.63	0.33	-0.43	-0.62	0.42	0.63	-0.3	0.92	0.27	0.94	-0.65	0.58
Non Currrent Assets Other	0.92	-0.56	0.21	0.56	0.67	0.25	-0.74	-0.46	-0.15	0.89	0.87		0.15	0.95	0.37	0.32	-0.39	-0.79	0.58	0.65	-0.32	0.78	0.22	0.92	-0.46	0.86
Long Term Debt	-0.18	0.47	0.56	-0.37	-0.4	-0.51	0.26	0.76	-0.95	0.48	-0.17	0.15		0.41	-0.2	-0.64	0.64	0.01	-0.33	-0.53	0.54	-0.17	-0.6	-0.18	0.68	0.48
Cash And Short Term Investments	0.8	-0.41	0.34	0.37	0.53	0.08	-0.62	-0.19	-0.41	0.94	0.78	0.95	0.41		0.31	0.07	-0.21	-0.75	0.38	0.43	-0.18	0.71	0.0	0.8	-0.21	0.92
Net Receivables	0.41	-0.11	0.32	0.83	0.27	0.73	-0.08	-0.34	0.2	0.01	0.63	0.37	-0.2	0.31		0.43	-0.3	0.12	-0.23	0.4	-0.14	0.83	0.54	0.38	-0.69	-0.08
Common Stock Shares Outstanding	0.39	-0.69	-0.51	0.75	0.7	0.89	-0.57	-0.89	0.8	-0.07	0.33	0.32	-0.64	0.07	0.43		-0.8	-0.18	0.51	0.89	-0.7	0.46	0.97	0.4	-0.88	-0.09
Non Current Liabilities Total	-0.48	0.94	0.72	-0.46	-0.93	-0.72	0.83	0.9	-0.72	-0.05	-0.43	-0.39	0.64	-0.21	-0.3	-0.8		0.53	-0.47	-0.9	0.98	-0.55	-0.78	-0.48	0.7	-0.07
Inventory	-0.77	0.77	0.23	-0.09	-0.78	0.03	0.9	0.48	0.04	-0.79	-0.62	-0.79	0.01	-0.75	0.12	-0.18	0.53		-0.71	-0.59	0.57	-0.46	-0.04	-0.78	0.19	-0.83
Other Current Assets	0.67	-0.66	-0.32	0.29	0.61	0.1	-0.72	-0.68	0.34	0.52	0.42	0.58	-0.33	0.38	-0.23	0.51	-0.47	-0.71		0.68	-0.44	0.18	0.29	0.69	-0.44	0.54
Other Stockholder Equity	0.71	-0.9	-0.46	0.71	0.92	0.75	-0.86	-0.95	0.63	0.3	0.63	0.65	-0.53	0.43	0.4	0.89	-0.9	-0.59	0.68		-0.82	0.68	0.82	0.72	-0.85	0.3
Total Liab	-0.37	0.95	0.81	-0.28	-0.91	-0.61	0.84	0.8	-0.64	-0.05	-0.3	-0.32	0.54	-0.18	-0.14	-0.7	0.98	0.57	-0.44	-0.82		-0.43	-0.69	-0.38	0.53	-0.1
Net Invested Capital	0.8	-0.52	0.18	0.78	0.67	0.62	-0.57	-0.56	0.14	0.46	0.92	0.78	-0.17	0.71	0.83	0.46	-0.55	-0.46	0.18	0.68	-0.43		0.48	0.78	-0.71	0.4
Property Plant And Equipment Gross	0.26	-0.62	-0.5	0.74	0.64	0.96	-0.47	-0.81	0.78	-0.2	0.27	0.22	-0.6	0.0	0.54	0.97	-0.78	-0.04	0.29	0.82	-0.69	0.48		0.26	-0.84	-0.22
Total Current Assets	1.0	-0.62	0.13	0.61	0.7	0.27	-0.75	-0.64	0.1	0.75	0.94	0.92	-0.18	0.8	0.38	0.4	-0.48	-0.78	0.69	0.72	-0.38	0.78	0.26		-0.62	0.72
Non Current Liabilities Other	-0.63	0.57	0.17	-0.92	-0.63	-0.84	0.49	0.88	-0.72	-0.03	-0.65	-0.46	0.68	-0.21	-0.69	-0.88	0.7	0.19	-0.44	-0.85	0.53	-0.71	-0.84	-0.62		0.03
Net Working Capital	0.71	-0.36	0.26	0.09	0.43	-0.23	-0.61	-0.09	-0.5	0.99	0.58	0.86	0.48	0.92	-0.08	-0.09	-0.07	-0.83	0.54	0.3	-0.1	0.4	-0.22	0.72	0.03

Click cells to compare fundamentals

Biofrontera Warrants Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Biofrontera Stock Analysis

When running Biofrontera Warrants' price analysis, check to measure Biofrontera Warrants' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera Warrants is operating at the current time. Most of Biofrontera Warrants' value examination focuses on studying past and present price action to predict the probability of Biofrontera Warrants' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera Warrants' price. Additionally, you may evaluate how the addition of Biofrontera Warrants to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biofrontera Current Deferred Revenue vs Capex To Revenue Analysis

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Capex To Revenue

Biofrontera Warrants fundamental ratios Correlations

Biofrontera Warrants Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Biofrontera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 0.99	Cash
Total Liab	+ 0.98	Non Current Liabilities Total
Property Plant And Equipment Gross	+ 0.97	Common Stock Shares Outstanding
Net Debt	+ 0.96	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.96	Property Plant And Equipment Net

Total Stockholder Equity	- 0.98	Short Long Term Debt Total
Net Debt	- 0.97	Total Stockholder Equity
Long Term Debt	- 0.95	Accounts Payable
Other Stockholder Equity	- 0.95	Retained Earnings
Non Current Liabilities Total	- 0.93	Total Stockholder Equity
Non Current Liabilities Other	- 0.92	Total Current Liabilities